Clinical Trial

BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

Name: BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy — clinical trial record (NCT07715136)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).

Trial Details

NCT Number	NCT07715136
Lead Sponsor	iCell Gene Therapeutics
Conditions	Inflammatory Myopathy
Enrollment	10 participants
Start Date	2025-03-20
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-20